Marinus pharmaceuticals zacks
Web12 mei 2024 · RADNOR, Pa. (AP) _ Marinus Pharmaceuticals Inc. (MRNS) on Thursday reported a loss of $19.4 million in its first quarter. The Radnor, Pennsylvania-based company said it had a loss of 52 cents per share. ... The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 87 cents per share. Web9 mrt. 2024 · Five analysts surveyed by Zacks expected $1.8 million. For the year, the company reported that its loss widened to $67.5 million, or $2.80 per share. Revenue was reported as $1.7 million. ADVERTISEMENT Marinus Pharmaceuticals shares have climbed 37% since the beginning of the year. The stock has increased 72% in the last 12 …
Marinus pharmaceuticals zacks
Did you know?
Web13 apr. 2024 · RADNOR, Pa.-- (BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of … Web26 jan. 2024 · Sasha Damouni Ellis Vice President, Investor Relations & Corporate Communications Marinus Pharmaceuticals, Inc. 484-253-6792 [email protected] Site Navigation Home
Web1 dag geleden · Zacks News for MRNS Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates 03/07/23-4:15PM EST Zacks Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates
WebBackground One of the challenges in the interpretation of studies showing associations between environmental and genotypic data with disease outcomes such as neovascular age-related macular degeneration (AMD) is understanding the phenotypic WebMarinus Pharmaceuticals, Inc. - Hold Zacks' proprietary data indicates that Marinus Pharmaceuticals, Inc. is currently rated as a Zacks Rank 3 and we are expecting an …
Web3 apr. 2024 · Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease.
Web18 mei 2024 · Participants who have received high-dose IV anesthetics (e.g., midazolam, propofol, thiopental, or pentobarbital) during the current episode of SE for more than 18 hours, or who continue to have clinical or electrographic evidence of persistent seizures while receiving high-dose IV anesthetics. ciee osaka uni okiniWeb12 mei 2024 · Marinus Pharmaceuticals, which belongs to the Zacks Medical - Drugs industry, posted revenues of $14.19 million for the quarter ended March 2024, … cie djudjuWeb15 jul. 2024 · Marinus Pharmaceuticals, Inc. (MRNS): Free Stock Analysis Report Aquestive Therapeutics, Inc. (AQST): Free Stock Analysis Report To read this article on … cie 10 tamizaje auditivoWeb15 jul. 2024 · Marinus currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall health sector are Aquestive Therapeutics AQST and Seagen SGEN, both … cieja rosa kazue inakake de souza profaWeb6 apr. 2024 · Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment … cid verruga nao viralWeb10 apr. 2024 · TipRanks. Apr. 10, 2024, 06:15 AM. Jefferies analyst Andrew Tsai maintained a Buy rating on Supernus Pharmaceuticals ( SUPN – Research Report) on April 8 and set a price target of $45.00. The ... ciee jovem aprendiz aracajuWeb7 mrt. 2024 · Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to... ciee sao luiz gonzaga